Citius Oncology reported preliminary results for its fiscal fourth quarter 2026, highlighting a significant acceleration in the commercial rollout of LYMPHIR. Sequential growth in unit shipments was driven by the expansion of the commercial team to nationwide coverage in August, though the company has not yet released full financial statements including dollar-denominated revenue or net income.
Key Highlights
- LYMPHIR unit sales to U.S. wholesalers reached 792 units in the fourth quarter, a 120% increase over the 360 units sold in the prior quarter.
- Prescribing centers ordered 950 vials from wholesalers during the period, representing modest sequential growth from the 926 vials ordered in the fiscal third quarter.
- Institutional adoption expanded to 54 ordering entities as of late October, moving toward management's target of 100 priority institutions by calendar year-end.